Cargando…

Ubiquitination in Scleroderma Fibrosis and Its Treatment

Scleroderma (systemic sclerosis, SSc) is a highly heterogeneous rheumatic disease, and uncontrolled fibrosis in visceral organs is the major cause of death in patients. The transforming growth factor-β (TGF-β) and WNT/β-catenin signaling pathways, along with signal transducer and activator of transc...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Ying, Chen, Weilin, Du, Qian, Zuo, Xiaoxia, Zhu, Honglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199354/
https://www.ncbi.nlm.nih.gov/pubmed/30386338
http://dx.doi.org/10.3389/fimmu.2018.02383
_version_ 1783365128042840064
author Long, Ying
Chen, Weilin
Du, Qian
Zuo, Xiaoxia
Zhu, Honglin
author_facet Long, Ying
Chen, Weilin
Du, Qian
Zuo, Xiaoxia
Zhu, Honglin
author_sort Long, Ying
collection PubMed
description Scleroderma (systemic sclerosis, SSc) is a highly heterogeneous rheumatic disease, and uncontrolled fibrosis in visceral organs is the major cause of death in patients. The transforming growth factor-β (TGF-β) and WNT/β-catenin signaling pathways, along with signal transducer and activator of transcription 3 (STAT3), play crucial roles in this fibrotic process. Currently, no therapy is available that effectively arrests or reverses the progression of fibrosis in patients with SSc. Ubiquitination is an important post-translational modification that controls many critical cellular functions. Dysregulated ubiquitination events have been observed in patients with systemic lupus erythematosus, rheumatoid arthritis and fibrotic diseases. Inhibitors targeting the ubiquitination pathway have considerable potential for the treatment of rheumatic diseases. However, very few studies have examined the role and mechanism of ubiquitination in patients with SSc. In this review, we will summarize the molecular mechanisms of ubiquitination in patients with SSc and explore the potential targets for treatment.
format Online
Article
Text
id pubmed-6199354
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61993542018-11-01 Ubiquitination in Scleroderma Fibrosis and Its Treatment Long, Ying Chen, Weilin Du, Qian Zuo, Xiaoxia Zhu, Honglin Front Immunol Immunology Scleroderma (systemic sclerosis, SSc) is a highly heterogeneous rheumatic disease, and uncontrolled fibrosis in visceral organs is the major cause of death in patients. The transforming growth factor-β (TGF-β) and WNT/β-catenin signaling pathways, along with signal transducer and activator of transcription 3 (STAT3), play crucial roles in this fibrotic process. Currently, no therapy is available that effectively arrests or reverses the progression of fibrosis in patients with SSc. Ubiquitination is an important post-translational modification that controls many critical cellular functions. Dysregulated ubiquitination events have been observed in patients with systemic lupus erythematosus, rheumatoid arthritis and fibrotic diseases. Inhibitors targeting the ubiquitination pathway have considerable potential for the treatment of rheumatic diseases. However, very few studies have examined the role and mechanism of ubiquitination in patients with SSc. In this review, we will summarize the molecular mechanisms of ubiquitination in patients with SSc and explore the potential targets for treatment. Frontiers Media S.A. 2018-10-17 /pmc/articles/PMC6199354/ /pubmed/30386338 http://dx.doi.org/10.3389/fimmu.2018.02383 Text en Copyright © 2018 Long, Chen, Du, Zuo and Zhu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Long, Ying
Chen, Weilin
Du, Qian
Zuo, Xiaoxia
Zhu, Honglin
Ubiquitination in Scleroderma Fibrosis and Its Treatment
title Ubiquitination in Scleroderma Fibrosis and Its Treatment
title_full Ubiquitination in Scleroderma Fibrosis and Its Treatment
title_fullStr Ubiquitination in Scleroderma Fibrosis and Its Treatment
title_full_unstemmed Ubiquitination in Scleroderma Fibrosis and Its Treatment
title_short Ubiquitination in Scleroderma Fibrosis and Its Treatment
title_sort ubiquitination in scleroderma fibrosis and its treatment
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199354/
https://www.ncbi.nlm.nih.gov/pubmed/30386338
http://dx.doi.org/10.3389/fimmu.2018.02383
work_keys_str_mv AT longying ubiquitinationinsclerodermafibrosisanditstreatment
AT chenweilin ubiquitinationinsclerodermafibrosisanditstreatment
AT duqian ubiquitinationinsclerodermafibrosisanditstreatment
AT zuoxiaoxia ubiquitinationinsclerodermafibrosisanditstreatment
AT zhuhonglin ubiquitinationinsclerodermafibrosisanditstreatment